admin

June 30, 2024

June 30, 2024

CureLab Oncology Files Patent Application for Groundbreaking Wound-Healing Therapy

Novel p62-based treatment accelerates wound healing and reduces complications
Do you like it?
Read more
June 14, 2024

June 14, 2024

Healing by Proxy: Newly Discovered Drug Elenagen May Treat Cancer and Inflammation Through Indirect Action

University of Camerino and CureLab Oncology announce strategic partnership to turn recent discovery into next-generation medicine
Do you like it?
Read more
March 25, 2024

March 25, 2024

CureLab Oncology Secures Patent Protection in Canada for Elenagen, Its P62 Plasmid Cancer Therapeutic

This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses
Do you like it?
Read more
September 29, 2023

September 29, 2023

CureLab seeks new strategic partners to bring cancer innovation to market

CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.
(This article republished with the kind permission of S&P Global)
Do you like it?
Read more
12345
© 2026 CureLab Veterinary